SEMI-ANNUAL REVIEW OF THE OMX HELSINKI 25 INDEX The new

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SEMI-ANNUAL REVIEW OF THE OMX HELSINKI 25 INDEX

The new portfolio of the OMX Helsinki 25 index will become effective on February 1, 2016.

Helsinki, January 11, 2016 — Nasdaq (Nasdaq: NDAQ ) announces today the results of the semi-annual review of the OMX Helsinki 25 index, (Nasdaq Helsinki: OMXH25), which will become effective with the market open on Monday, February 1, 2016.

Nasdaq reports that there are no changes to the OMXH25 constituent list in this semi-annual review.

The OMX Helsinki 25 Index, launched in 1988, is the leading equity index for the Finnish equity market including the 25 most traded Blue chip companies on Nasdaq Helsinki. The index is designed to track the Finnish equity market and act as underlying for financial products such as options, futures, exchange-traded funds and mutual funds.

The OMX Helsinki 25 index constituents effective February 1, 2016, are:

Amer Sports Corporation Metso Corporation Sampo Plc A
Cargotec Oyj B Neste Corporation Stora Enso Oyj R
Elisa Corporation Nokia Corporation TeliaSonera AB
Fortum Corporation Nokian Tyres Plc Tieto Oyj
Huhtamäki Oyj Nordea Bank AB FDR UPM-Kymmene Corporation
Kemira Oyj Orion Corporation B Valmet Oyj
Kesko Corporation B Outokumpu Oyj Wärtsilä Corporation
KONE Oyj B Outotec Oyj YIT Corporation
Konecranes Plc    
     
About Nasdaq Indexes        

Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index and design solutions to financial organizations worldwide. For more information about Nasdaq indexes, visit https://indexes.nasdaqomx.com/ .

About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit nasdaq.com/ambition or business.nasdaq.com .

Cautionary Note Regarding Forward-Looking Statements

Information set forth in this communication contains forward-looking statements that involve a number of risks and uncertainties.  Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information.  Such forward-looking statements include, but are not limited to, statements about our capital return initiatives.  Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq’s control.  These factors include, but are not limited to, Nasdaq’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors detailed in Nasdaq’s filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q.  Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Relations Contact : +        Heli-Kirsti Airisniemi +        + 358 (0)9 6166 7941 +        heli-kirsti.airisniemi@nasdaq.com  
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 14

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 13

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 14

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 9

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 14

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 15

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 14

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 11

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 8

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Telehealth Trends: A Comprehensive Yearly Insight

Updated Category News Views 346

FAIR Health's Telehealth Tracker: A Milestone Year FAIR Health has reached a significant milestone with its Monthly Telehealth Regional Tracker entering its sixth year. This tracker provides valuable insights into how telehealth usage has evolved, empowering stakeholders to understand trends in healthcare delivery. New Features and Data Insights The latest iteration of...

Continue Reading
Exploring Analog Devices: A $1000 Investment Journey

Updated Category News Views 139

The Growth of Analog Devices Inc (NASDAQ: ADI) Investors have increasingly turned their attention to Analog Devices Inc, a leader in the semiconductor industry. Over the last five years, Analog Devices has consistently outperformed the market, showcasing an annualized return of 16.0%. With a current market capitalization standing at an impressive $119.42 billion, the...

Continue Reading
Celebrating Excellence in Clinical Simulation: Meet the Nominees

Updated Category News Views 110

Highlighting Excellence in Clinical Simulation Awards A Representation of the Best in Simulation Healthcare Education in 2024 Education Management Solutions (EMS), a frontrunner in healthcare simulation and competency management platforms, has proudly announced its nominees for the 16th Annual Excellence in Clinical Simulation Awards. Each year, this noteworthy event...

Continue Reading
Significant Oil Price Drop Benefits Airlines and Cruise Lines

Updated Category News Views 195

Oil Prices Experience a Significant Drop Amid Easing Tensions Oil prices witnessed a noticeable decrease recently, plummeting over 5% during early trading in New York. This shift came as geopolitical tensions in the Middle East appeared to stabilize after an assurance from Israeli Prime Minister Benjamin Netanyahu that Iran’s oil facilities would not be targets in any...

Continue Reading
RxSight, Inc. Faces Legal Challenges: Investors Invited to Join Lawsuit

Updated Category News Views 136

RxSight, Inc. Investors Invited to Participate in Class Action Lawsuit Investors of RxSight, Inc. are becoming aware of significant opportunities to engage in a class action lawsuit. This legal action is being initiated by Bronstein, Gewirtz & Grossman, LLC, a law firm with a national reputation for advocating on behalf of investors. They are notifying shareholders that...

Continue Reading